7 Analysts Have This to Say About Guardant Health
Analysts have provided the following ratings for Guardant Health (NASDAQ:GH) within the last quarter: Bullish Somewhat Bullish Indifferent…
Cancer Test Firm Guardant Health Posts Smaller Than Expected Q3 Loss, Lifts Annual Sales Outlook
Guardant Health Inc (NASDAQ: GH) reported Q3 revenue of $143 million, up 22% Y/Y, beating the consensus of $137.37 million
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell
• Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
The Latest Analyst Ratings for Guardant Health
Over the past 3 months, 7 analysts have published their opinion on Guardant Health (NASDAQ:GH) stock. These analysts…
Benzinga’s Top Ratings Upgrades, Downgrades For September 28, 2023
Upgrades According to Northcoast Research, the prior rating for Essential Utilities Inc (NYSE:WTRG) was changed from Neutral to…
Guardant Health Has ‘Underlying Business Strength’ Says This Bullish Analyst
Shares of Guardant Health Inc (NASDAQ: GH) climbed during the premarket trading session and morning on Wednesday.
Benzinga’s Top Ratings Upgrades, Downgrades For September 27, 2023
Upgrades For Telos Corp (NASDAQ:TLS), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform. In…
Analyst Expectations for Guardant Health’s Future
Over the past 3 months, 4 analysts have published their opinion on Guardant Health (NASDAQ:GH) stock. These analysts…
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.
Guardant Health Provides Update On COBRA Study, Restates Confidence In MRD Test
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study.
The COBRA study was designed to evaluate